Diasulin 30/70 100 IU

Diasulin 30/70 – Biphasic Human Insulin 100 IU/ml by Opsonin Pharma

What is Diasulin 30/70?

Diasulin 30/70 is a premixed biphasic human insulin manufactured by Opsonin Pharma Ltd., Bangladesh. Each ml contains 30 IU soluble regular human insulin (short-acting, for post-meal glucose control) and 70 IU isophane insulin human (intermediate-acting NPH, for basal coverage). Produced using recombinant DNA (rDNA) technology, it provides both prandial and basal insulin coverage in a single twice-daily injection — making it a widely prescribed, cost-effective option for Type 2 diabetes management in Bangladesh. As a cloudy suspension, it must be resuspended by rolling and inverting before each injection.

Generic Name and Composition

Each ml: 30 IU soluble human insulin (onset 30 min, peak 1–3 hrs, duration 6–8 hrs) + 70 IU isophane human insulin (NPH, onset 1–2 hrs, peak 4–8 hrs, duration up to 18–24 hrs). The two components are produced by rDNA technology in yeast or E. coli and are identical in structure to endogenous human insulin. The 30/70 ratio delivers rapid post-meal coverage from the soluble fraction while the NPH fraction provides sustained basal coverage through the day.

Indications

• Type 2 diabetes mellitus — twice-daily premixed insulin regimen
• Type 1 diabetes — when a fixed premixed regimen is clinically appropriate
• Patients transitioning from oral antidiabetic agents to insulin
• Adults requiring affordable, established insulin therapy

How It Works — Mechanism of Action

Soluble component (30%): Acts as regular short-acting insulin — absorbed within 30 minutes, peaks at 1–3 hours to control post-meal glucose spikes. Isophane component (70%): NPH insulin slowly releases over 12–18 hours, providing basal glucose suppression between meals and overnight. Both components bind insulin receptors, activating GLUT-4-mediated glucose uptake in muscle and fat, and suppressing hepatic glucose output.

Dosage and Administration

Starting dose (Type 2): Typically 0.2 IU/kg/day divided into 2 doses (before breakfast and before dinner). Titration: Adjust by 2 IU every 3 days based on fasting and pre-dinner glucose readings. Administration: Resuspend by rolling the vial 10 times then inverting 10 times until uniformly milky. Draw up with insulin syringe. Inject subcutaneously into abdomen, thigh, or upper arm. Inject 30 minutes before meals due to onset of 30 minutes.

Side Effects

Very common: Hypoglycaemia — risk is higher if meals are delayed or dose is excessive.

Common: Injection site reactions (redness, swelling, bruising), lipohypertrophy with repeated injections at same site, weight gain.

Uncommon: Lipoatrophy, peripheral oedema, visual changes at therapy initiation.

Rare: Systemic allergic reactions, anaphylaxis.

Drug Interactions

Increase hypoglycaemia: Oral antidiabetics, GLP-1 agonists, SGLT-2 inhibitors, ACE inhibitors, MAO inhibitors, salicylates, sulfonamides, alcohol.

Reduce insulin effect: Corticosteroids, glucagon, thyroid hormones, sympathomimetics, danazol, oral contraceptives, thiazide diuretics.

Mask hypoglycaemia symptoms: Beta-blockers, clonidine.

Contraindications

• Hypersensitivity to human insulin or any excipient
• Active hypoglycaemia episode; intravenous or intramuscular use

Pregnancy and Lactation

Pregnancy: Human insulin is considered safe during pregnancy; specialist monitoring essential to adjust doses as requirements increase in the second and third trimesters. Lactation: Insulin does not pass into breast milk at clinically significant levels.

Precautions and Warnings

• Always resuspend before use: Roll 10 times, invert 10 times. Never inject clear Diasulin 30/70 — it means the suspension has not been properly mixed.
• Inject 30 minutes before meals to match the slower onset of soluble human insulin vs. insulin analogues.
• Do not mix Diasulin 30/70 with other insulins in the same syringe.
• Rotate injection sites to prevent lipohypertrophy.
• Do not freeze. Discard if frozen.

Overdose

Hypoglycaemia. Mild: oral glucose or sugar. Moderate: oral glucose gel. Severe: IV 25–50% dextrose or IM/SC glucagon 1 mg. Monitor blood glucose every 2–4 hours until stable given the extended NPH component duration.

Storage Instructions

• Unopened vial: 2–8°C (refrigerator). Do not freeze.
• In-use vial: Below 25°C. Protect from direct sunlight and heat.
• Discard 28 days after first use, even if insulin remains.

Frequently Asked Questions

Q1: Why must Diasulin 30/70 be rolled and inverted before injection?
Diasulin 30/70 is a suspension — the NPH (isophane) crystals settle to the bottom on standing. Rolling and inverting 10 times each resuspends the crystals evenly, ensuring you inject the correct 30/70 ratio. Injecting without resuspension delivers an incorrect ratio, causing unpredictable glucose control.

Q2: How is Diasulin 30/70 different from insulin analogues like NovoMix 30?
Both are biphasic 30/70 premixed insulins, but Diasulin uses human insulin (onset 30 min) while NovoMix 30 uses insulin aspart analogue (onset 10–20 min). Diasulin must be injected 30 min before meals; NovoMix can be injected just before eating. Diasulin is significantly more affordable, making it the standard choice in Bangladesh's public health system.

Q3: Who manufactures Diasulin?
Diasulin is manufactured by Opsonin Pharma Ltd., a leading Bangladeshi pharmaceutical company, using recombinant DNA technology. Opsonin Pharma produces a range of human insulin formulations including Diasulin 30/70, Diasulin N (isophane), and Diasulin 50/50.

Q4: Can I switch from Diasulin 30/70 to an insulin analogue?
Yes, but switching requires medical supervision and dose adjustment. Insulin analogues (e.g., NovoMix 30, Ryzodeg) have different onset and duration profiles. Your diabetologist will recalculate your dose based on your current control and glucose patterns.

Medical Disclaimer: For educational purposes only. Diasulin 30/70 is Rx-only. Consult your diabetologist before starting or changing insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy in Bangladesh.